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Abstract
Background: Neuroglial cells that provide homeostatic support and form defence of the nervous system contribute to
all neurological disorders. We analyzed three major types of neuroglia, astrocytes, oligodendrocytes, and microglia in
the brains of an animal model of autism spectrum disorder, in which rats were exposed prenatally to antiepileptic and
mood stabilizer drug valproic acid; this model being of acknowledged clinical relevance.
Methods: We tested the autistic-like behaviors of valproic acid-prenatally exposed male rats by performing
isolation-induced ultrasonic vocalizations, the three-chamber test, and the hole board test. To account for
human infancy, adolescence, and adulthood, such tasks were performed at postnatal day 13, postnatal day
35, and postnatal day 90, respectively. After sacrifice, we examined gene and protein expression of specific
markers of neuroglia in hippocampus, prefrontal cortex, and cerebellum, these brain regions being associated
with autism spectrum disorder pathogenesis.
Results: Infant offspring of VPA-exposed dams emitted less ultrasonic vocalizations when isolated from their
mothers and siblings and, in adolescence and adulthood, they showed altered sociability in the three chamber test
and increased stereotypic behavior in the hole board test. Molecular analyses indicate that prenatal valproic
acid exposure affects all types of neuroglia, mainly causing transcriptional modifications. The most prominent
changes occur in prefrontal cortex and in the hippocampus of autistic-like animals; these changes are particularly evident
during infancy and adolescence, while they appear to be mitigated in adulthood.
Conclusions: Neuroglial pathological phenotype in autism spectrum disorder rat model appears to be rather mild with
little signs of widespread and chronic neuroinflammation.
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Background
Autism spectrum disorder (ASD) is a heterogeneous set of
neurodevelopmental disorders characterized by deficits in
social communication and social interaction, stereotypies,
and reduced patterns of behaviors [1, 2]. Even though ASD
can be diagnosed at any age, symptoms generally appear in
the childhood and last throughout a person’s life. Although
about 1% of the world population suffers from ASD [3], lit-
tle is known on ASD etiology and pathogenesis. Genetic
predispositions, maternal stressors, environmental factors,
infectious agents, and the intake of specific drugs during
pregnancy all have some degree of association with ASD
[4]. One of the common environmental factors involved in
the pathogenesis of ASD is maternal exposure to the anti-
epileptic and mood stabilizer drug valproic acid (VPA).
When given during pregnancy, VPA was reported to induce
various congenital malformations [5, 6] including autistic-
like features in the exposed children, such as impaired com-
munication, reduced sociability and stereotyped behaviors
[7, 8]. Based on these clinical observations, prenatal VPA
exposure in rodents has been developed and became a
widely used environmental preclinical model of ASD with
face and construct validity [9–11].
Recent findings highlight contribution of neuroglia to
the ASD pathophysiology. Glial cells are non-excitable
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homeostatic cells of the central nervous system (CNS),
sub-classified into astrocytes, oligodendrocytes and their
precursors (also known as NG-2 glia) and microglia; all
types of glia sustain vital brain functions [12]. Specific-
ally, astroglial cells are key cellular contributors to the
homeostasis of the nervous tissue and the brain as an
organ [13–16]. Astrocytes regulate pH and ion homeo-
stasis, regulate functional hyperaemia and provide
trophic and metabolic support to neurones. Astrocytes
are important elements of the cytoarchitecture of the
brain. These cells are essential for synaptogenesis [17,
18] as well as synaptic remodeling and are likely to con-
tribute to various aspects of memory formation, storage,
and retention [19]. Oligodendrocytes form the myelin
sheath, thus maintaining the functional connectome of
the brain and contributing to the optimal information
processing in complex neural networks [20]. Microglia
provide the immune and cellular defence in the brain.
Through several surveillance mechanisms, microglia de-
tect diverse pathological extracellular signals, and respond
to them to protect the brain. These cells also contribute to
the development of the nervous tissue, shaping neuronal
ensembles and synaptic plasticity [21–24].
Increasing appreciation of the multifaceted physiological
roles of glia in the developing and mature CNS suggests
that abnormalities in glial functions contribute to neuro-
pathology. Several preclinical models of diseases revealed
the role of glia in neurodevelopmental diseases, from ASD
to neuropsychiatric disorders. Pathological changes in
neuroglia are complex and can be classified into reactive
response (astrogliosis, activation of microglia, and Waller-
ian remodeling of oligodendrocytes), degeneration with at-
rophy and loss of function (characteristic for astrocytes
and microglia), and pathological remodeling [25–27]. The
contribution of glial cells to pathological development of
cognitive and neuropsychiatric disorders, such as Alzhei-
mer’s disease, Parkinson’s disease, depression, schizophre-
nia, and others, has been demonstrated [28–36]. The role
of glia in ASD however is not clear and often the data
available are limited to their involvement in the inflamma-
tory response.
In this study, we performed an in-depth analysis of
gene and protein expression of specific markers of astro-
cytes, oligodendrocytes, and microglia in the rats pre-
natally exposed to VPA (ASD animal model). We
studied brain areas critically involved in ASD, namely,
hippocampus (HPC), prefrontal cortex (PfC), and cere-
bellum (Cb) [37–39]. To account for human infancy,
adolescence, and adulthood, brain tissues were analyzed
at three different ages, at postnatal day (PND) 13, PND
35, and PND 90. Our results indicate that prenatal VPA
exposure affects all types of neuroglia, mainly causing
transcriptional modifications. The most significant
changes occur in PfC and in the HPC of autistic-like
animals; these changes are particularly evident during
infancy and adolescence, while they appear to be miti-
gated in adulthood.
Methods
All animal procedures were performed in agreement
with the guidelines of the Italian Ministry of Health
(D.L. 26/2014) and with the European Parliament direct-
ive 2010/63/EU.
Animals
The offspring born from VPA-exposed dams was obtained
as described previously [40]. Adult female Wistar rats
(Charles River, Arbresle, France) were housed and raised
under controlled conditions (22 ± 2 °C temperature, 55–
65% relative humidity, 12-h light/12-h dark cycle with
lights on at 07:00 h) in an enriched environment, with
food and water available ad libitum. Rats weighing 250 ±
15 g were mated overnight, and the morning when sperm-
atozoa were found was assigned as gestational day 1 (GD
1). Pregnant rats, singly placed in Macrolon cages (40 ×
26 × 20 cm), on GD 12.5, received an intraperitoneal injec-
tion of either VPA (500mg/kg in saline) or saline (Veh).
This dose of VPA, administered at this developmental
time point, is known to induce autistic-like traits in the
exposed rat offspring at infancy, adolescence, and adult-
hood [41]. The day after birth (PND 1), the litters were
culled to six males and two females to reduce the litter
size-induced variability in the growth and development of
pups during the postnatal period. However, epidemio-
logical studies report a higher incidence of ASD in boys
than in girls, and it has been shown that the
autistic-like-behaviors displayed by rats prenatally exposed
to VPA are more pronounced in the male than in the fe-
male offspring [42, 43]. For these reasons, only the male
offspring was used in this study. After weaning on PND
21, pups were weaned and housed in groups of three. In
order to perform the molecular analysis of the brains in
infancy, adolescence, and adulthood, the male offspring
(one rat/litter/treatment) was sacrificed on PND 13, PND
35, and PND 90, respectively. After decapitation, PfC,
HPC, and Cb were rapidly isolated to perform western
blot and real time-quantitative PCR (RT-qPCR); whereas,
whole brains for immunofluorescence were flash-frozen in
2-methylbutane and stored at − 80 °C. The experimental
design is outlined in Fig. 1a.
Behavioral tests
Isolation-induced ultrasonic vocalizations (USVs)
On PND 13, the USVs emitted by each pup removed
from the nest and placed into a Plexiglas arena were de-
tected for 3 min by an ultrasound microphone (Avisoft
Bioacoustics, Germany) sensitive to frequencies between
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10 and 200 kHz. The USVs were analyzed quantitatively
using Avisoft Recorder software (Version 5.1).
Three-chamber test
The test was performed as previously described [40].
The apparatus was a rectangular three-chamber box,
with two lateral chambers (30 l × 35 w × 35 h cm) con-
nected to a central chamber (15 l × 35 w × 35 h cm).
Each lateral chamber contained a small Plexiglas cylin-
drical cage. At PND 35, each experimental rat was indi-
vidually allowed to explore the three-chamber apparatus
for 10 min, and then confined in the central compart-
ment. An unfamiliar stimulus animal was confined in a
cage located in one chamber of the apparatus, while the
cage in the other chamber was left empty. Both doors to
the side chambers were then opened, allowing the ex-
perimental animal to explore the apparatus for 10 min.
The percent of time spent in social approach (sniffing
the stimulus animal) were scored using the Observer 3.0
software (Noldus, The Netherlands).
Hole board test
The apparatus was a gray square metal table (40 l × 40
w × 10 h cm) with 16 evenly spaced holes (4 cm in diam-
eter), inserted in a Plexiglas arena (40 l × 40 w × 60 h
cm). At PND 90, rats were individually placed in the ap-
paratus and their behavior was observed for 5 min. Dip-
ping behavior was scored by the number of times an
animal inserted its head into a hole at least up to the eye
level. Each session was recorded with a camera posi-
tioned above the apparatus for subsequent behavioral
analysis performed using the Observer 3.0 software
(Noldus Information Technology).
Real-time quantitative PCR (RT-qPCR)
Total mRNA of PfC, HPC, and Cb was isolated by
TRI-Reagent (Sigma-Aldrich, Saint Louis, MO, USA) fol-
lowing the manufacturer’s instructions. For each brain tis-
sue, the total amount of the mRNA was quantified by D30
BioPhotometer spectrophotometer (Eppendorf AG, Ham-
burg, Germany). The first-strand cDNA synthesis kit, add-
ing oligo (dT) 0.2 μM and random primers 0.05 μg/μl was
Fig. 1 Effect of prenatal VPA exposure on animals’ behavior. Schematic representation of the experimental design (a). Assessment of the
autistic-like phenotype in prenatally VPA-exposed rats through reduced isolation-induced USV emission at PND 13 (b), sociability in the
three-chamber test at PND 35 (c), and induced stereotypic behavior in the hole-board test at PND 90 (d) (Veh n = 5, VPA n = 5). Data
represent mean ± SEM. Statistical analysis was performed by t test (*p < 0.05 vs Veh group)
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used to perform revers transcription of 1 μg mRNA
to obtain cDNA (Promega, Promega Corporation, WI,
USA). Reverse transcription was carried out with the
following thermal protocol: + 25 °C for 10 min and +
72 °C for 65 min. Samples were stored at + 4 °C and
then processed for mRNA encoding for S100B, glial
fibrillary acidic protein (GFAP), Olig2, Iba1 (Bio-Fab
laboratories, Rome, Italy), and the cluster of differen-
tiation 11b (CD11b) (Bio-Rad, Hercules, CA, USA).
To confirm pair’s primers efficiency, the amplification
products from each primer pair were tested with the
melting curve analyses. The amounts of the amplicons
were normalized against TATA-box binding protein
(TBP) and hypoxanthine guanine phosphoribosyl trans-
ferase (HPRT) used as reference genes (all primers se-
quences are listed in Table 1). All amplifications were
performed dissolving 500–800 nM primers and 75 ng
cDNA in the iTaq Universal SYBR Green Supermix
(Bio-Rad) using a CFX96 Touch thermocycler (Bio-Rad)
according to the manufacturer’s instructions. The detec-
tion of the fluorescent signals was assessed at the end of
the + 60 °C extension period. For each sequence of inter-
est, three independent experiments were performed in
triplicate. Data are expressed as the fold difference in
mRNA expression (ΔΔCq) calculated according to the
Pflaffl method.
Western blot
Total protein amount of PfC, HPC, and Cb was iso-
lated and processed as previously described [29, 30,
34]. Brain tissues were mechanically lysed in ice-cold
hypotonic lysis buffer containing 50 mM Tris/HCl pH
7.5, 150 mM NaCl, 1 mM ethylenediamenetetraacetic
acid (EDTA), 1% triton X-100, 1 mM
phenylmethylsulfonyl fluoride (PMSF), 10 μg/ml apro-
tinin, and 0.1 mM leupeptin (all from Sigma-Aldrich),
and then incubated for 40 min at + 4 °C. After centri-
fugation at 14000 rpm for 30 min, supernatants were
collected and stored at − 80 °C. Protein concentration
was calculated by Bradford assay to resolve an equal
amount of proteins for each sample. Thirty micro-
grams were resolved through 12% acrylamide
SDS-PAGE gel and then transferred onto nitrocellu-
lose membranes with a trans-blot semi-dry transfer
cell (Bio-Rad). From this step on, membranes were
treated on an orbital shaker. Unspecific bound of the
antibodies was avoided by incubating membranes for
1 h at room temperature in a blocking solution con-
taining either 5% non-fat dry milk (Bio-Rad) or 5%
bovine serum albumin (BSA, Sigma-Aldrich) in
tris-buffered saline (TBS) (Corning, NY, USA) 0.1%
tween 20 (TBS-T). Then, an overnight incubation
with the proper primary antibodies against S100B,
GFAP, Olig2, CD11b, or Iba1 was performed at + 4 °C
(experimental conditions are reported in Table 2).
After removing the excess of antibody solution, the mem-
branes were rinsed in TBS-T 0.05% and incubated for 1 h
at room temperature with a specific secondary horseradish
peroxidase (HRP)-conjugated antibody (Table 2) to detect
immunocomplexes by an enhanced chemiluminescence
(ECL) kit (GE Healthcare Life Sciences, Milan, Italy).
Immunocomplexes were visualized using a Chemidoc XRS
+ and Image Lab software (Bio-Rad), and then quantified
by ImageJ software. Values were normalized to those of
β-actin.
For each protein of interest, three independent experi-
ments were performed in triplicate. Data are expressed
as percentage of control.
Table 1 Primer sequences and general conditions used to perform real-time qPCR
GENE Primer (5′→ 3′) Annealing (°C) Efficiency (%) R2
S100B Forward TCAGGGAGAGAGGGTGACAA 60 94.6 .998
Reverse ACACTCCCCATCCCCATCTT
GFAP Forward CGGCTCTGAGAGAGATTCGC 60 105.0 .989
Reverse GCAAACTTGGACCGATACCA
Olig2 Forward CCCGATGATCTTTTTCTGCC 60 98.8 .990
Reverse GCTTCTTATCTTTCTTGGTG
CD11b Forward N/A (Cod. qRnoCID0002800, Bio-Rad) 60 94.0 .990
Reverse
Iba1 Forward GTCCTTGAAGCGAATGCTGG 60 95.6 .994
Reverse CATTCTCAAGATGGCAGATC
HPRT Forward TCCCAGCGTCGTGATTAGTGA 60 98.3 .992
Reverse CCTTCATGACATCTCGAGCAAG
TBP Forward TGGGATTGTACCACAGCTCCA 60 99.7 .995
Reverse CTCATGATGACTGCAGCAAACC
GFAP glial fibrillary acidic protein; CD11b cluster of differentiation 11b; HPRT hypoxanthine guanine phosphoribosyl transferase; TBP TATA-box binding protein
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Immunofluorescence
Immunofluorescence was performed as previously de-
scribed [30, 34, 44]. The assay was performed on
12-μm-thick coronal slices of PfC, HPC, and Cb. Tis-
sues were rinsed in phosphate-buffered saline (PBS)
and post-fixed with 4% paraformaldehyde (PFA). After
the blocking step lasting 90 min at room temperature
in 1% BSA dissolved in PBS/0.25% triton X-100, sec-
tions were incubated overnight with the primary anti-
body recognizing GFAP, Olig2, or Iba1 at + 4 °C.
Primary antibodies were diluted in 0.5% BSA in PBS/
0.25% triton X-100. Tissues were rinsed in PBS and in-
cubated for 2 h at room temperature with the proper
secondary antibody. The staining of nuclei was
performed with Hoechst (1:5000, Thermo Fisher Sci-
entific, MA, USA). After rinses in PBS slices were
mounted with Fluoromount aqueous mounting
medium (Sigma-Aldrich). The experimental conditions
are summarized in Table 3.
Cell count analysis
Cells labeled with the different markers were quantified in
4 serial coronal 12 μm sections, spaced 48 μm apart, in
each brain region for each animal. We used three rats per
experimental group (N = 3 vehicle and N = 3 VPA) for
each age, for a total of 18 rats. The brain regions analyzed
were the PfC, the molecular layer (ML) and the granular
cell layer (GL) of the Cb, the stratum radiatum of the
Ammon’s horn 1 (CA1), CA2, CA3, and hilus of the den-
tate gyrus (DG) of the HPC. Nuclei were stained with
Hoechst dye. Cells were identified as positive for a marker
if they expressed immunoreactivity visually deemed to be
above background. Images were captured using a × 20/
0.50 magnification objective, and digitization was executed
with a wide-field microscope (Eclipse E600; Nikon Instru-
ments, Rome, Italy) connected to a QImaging camera with
NIS-Elements BR 3.2 64-bit software. We used a 200 ×
100 × 12 μm capture field of view to analyze the number
of immunopositive cells within each field using the
multi-point button of the Fiji Is Just ImageJ (FIJI) software.
Cell count analyses, expressed as number of antibody
positive cells in 2.4 × 105 μm3 of tissue, were carried out
by a blind observer.
Statistical analysis
GraphPad Prism 6 software (GraphPad Software, San
Diego, CA, USA) was used for the statistical analyses.
Student’s t test was used to compare Veh and VPA
Table 2 Experimental conditions used to perform western blot experiments
Primary antibody Brand/cat # Dilution Secondary antibody Brand/cat #
Rabbit α-S100B Genetex 1:1000 HRP conjugated goat anti-rabbit IgG 1:10000 Jackson ImmunoResearch
GTX129573 5% BSA in TBS-T 0.1% 5% BSA in TBS-T 0.1% 111-035-045
Rabbit α-GFAP Abcam 1:25000 HRP conjugated goat anti-rabbit IgG 1:10000 Jackson ImmunoResearch
ab7260 5% milk in TBS-T 0.1% 5% milk in TBS-T 0.1% 111-035-045
Rabbit α-Olig2 Santa Cruz 1:500 HRP conjugated goat anti-rabbit IgG 1: 10000 Jackson ImmunoResearch
sc-48817 5% milk in TBS-T 0.1% 5% milk in TBS-T 0.1% 111-035-045
Rabbit α-CD11b Bioss 1:1000 HRP conjugated goat anti-rabbit IgG 1:10000 Jackson ImmunoResearch
bs-1014R 5% BSA in TBS-T 0.1% 5% BSA in TBS-T 0.1% 111-035-045
Rabbit α-Iba1 Abcam 1:1000 HRP conjugated goat anti-rabbit IgG 1:10000 Jackson ImmunoResearch
ab178846 5% milk in TBS-T 0.1% 5% milk in TBS-T 0.1% 111-035-045
Rabbit α-β-actin Santa Cruz 1:1000 HRP conjugated goat anti-rabbit IgG 1:20000 Jackson ImmunoResearch
sc-1616R 5% milk in TBS-T 0.1% 5% milk in TBS-T 0.1% 111-035-045
GFAP glial fibrillary acidic protein; CD11b cluster of differentiation 11b; MAP2 microtubule associated protein; BSA bovine serum albumin; TBS-T tris buffered saline
tween 20; HRP horseradish peroxidase
Table 3 Experimental conditions used to perform immunofluorescence
Primary antibody Brand/cat # Dilution Secondary antibody Brand/cat #
Rabbit α-GFAP Abcam 1:200 FITC conjugated goat anti-rabbit IgG (H + L)
1:200, 5% BSA in PBS/0.25% triton X-100
Jackson ImmunoResearch
ab7260 5% BSA in PBS/0.25% triton X-100 111-095-003
Rabbit α-Olig2 Santa Cruz 1:250 FITC conjugated goat anti-rabbit IgG (H + L)
1:200, 0.5% BSA in PBS/0.25% triton X-100
Jackson ImmunoResearch
sc-48817 0.5% BSA in PBS/0.25% triton X-100 111-095-003
Rabbit α-Iba1 Wako 1:1000 FITC conjugated goat anti-rabbit IgG (H + L)
1:200, 0.5% BSA in PBS/0.25% triton X-100
Jackson ImmunoResearch
019-19741 0.5% BSA in PBS/0.25% triton X-100 111-095-003
GFAP glial fibrillary acidic protein; MAP2 microtubule associated protein; BSA bovine serum albumin; FITC fluorescein isothiocyanate; PBS phosphate buffered saline
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groups. Data are presented as mean ± SEM. Differences
between means were considered as significant at p < 0.05.
Results
Behavioral tests
Animals prenatally exposed to VPA showed enduring im-
pairments in the three core symptoms of autism. At in-
fancy, VPA-exposed pups separated from the dam and
siblings vocalized significantly less compared to Veh-ex-
posed pups (t = 2.334; p < 0.05; df = 8, Fig. 1b). At adoles-
cence, VPA-exposed rats showed decreased sociability in
the three-chamber test, since they spent less time sniffing
the stimulus animal compared to Veh-exposed animals
(t = − 2.436; p < 0.05; df = 8, Fig. 1c). At adulthood,
VPA-exposed rats showed stereotypic behaviors in the
hole board test, since they made more head dipping at
PND 90 (t = − 2.781; p < 0.05; df = 8, Fig. 1d).
In their entirety, these results confirm that prenatal
exposure to VPA causes the manifestation of autistic-like
behaviors that persist from infancy to early adulthood.
Astrocytes in ASD model rats
To investigate the effect of prenatal VPA exposure on
astrocyte phenotype, we analyzed transcription and ex-
pression of the archetypal astroglial markers GFAP and
the neurotrophin/Ca2+ binding protein S100B. At PND
13, we observed a significant reduction of S100B mRNA
in the HPC of VPA-exposed rats compared to control
animals, with no significant modification in its protein
expression (Fig. 2a, b). At the same age, we detected a
significant increase of GFAP mRNA in the HPC of
VPA-exposed rats (Fig. 2c). No changes in GFAP protein
were observed among all groups by western blot
(Fig. 2d); however, immunofluorescence experiments re-
vealed a significant increase of GFAP-positive cells in
the PfC of VPA-exposed rats (Fig. 2e, f ).
At PND 35 rats showed higher levels of S100B mRNA
in both PfC and HPC of VPA-exposed rats, with a sig-
nificant reduction in the Cb (Fig. 3a). A decreased level
of GFAP mRNA was found in the PfC and in the Cb of
VPA animals compared to controls (Fig. 3c). No modifi-
cations of S100B levels were found at protein level
(Fig. 3b), whereas GFAP protein expression was higher
in the PfC of VPA-exposed rats (Fig. 3d).The number of
GFAP-positive cells was decreased in the GL of the Cb,
and in the CA1 and DG hippocampal sub-regions, while
a significant increase of GFAP-positive astrocytes was
observed in the CA3 of VPA-exposed rats (Fig. 3e, f ).
Results obtained in adult rats demonstrate transcrip-
tional modifications and some alterations in protein con-
tent. At PND 90, VPA-exposed animals showed higher
levels of S100B mRNA in Cb and HPC (Fig. 4a). Con-
versely, GFAP mRNA was lower in the HPC and higher
in the Cb of VPA-exposed rats compared to Veh animals
(Fig. 4c). No changes in the protein expression of GFAP
and S100B were detected (Fig. 4b, d). Finally, signifi-
cantly higher number of GFAP-positive cells in the ML
of the Cb and CA2 of the HPC of VPA-exposed rats was
documented (Fig. 4e, f ).
In summary, prenatal exposure to VPA differentially
affects astrocytes in different brain regions, and causes
transcriptional modifications of S100B and GFAP, which
are particularly evident in adolescent and adult rats,
where modified GFAP expression is also observed.
Oligodendrocytes in ASD model rats
We examined the effects of prenatal exposure to VPA
on oligodendrocytes by testing Olig2, a transcriptional
factor essential for oligodendrocyte development. Infant
VPA-exposed rats showed higher levels of Olig2 mRNA
in PfC and HPC, and a trend toward an increase of
Olig2 protein expression (+ 76.77%) in PfC compared to
age-matched control animals (Fig. 5a, b). No changes of
Olig2-positive cells density were observed, except for the
CA3 sub-region of the HPC where a significant decrease
of their population was detected (Fig. 5c, d).
The RT-qPCR analysis revealed a significant increase
of Olig2 in the PfC of VPA-exposed rats at PND 35, with
a decrease of this transcription factor in the HPC of the
same animals (Fig. 6a). These modifications were evident
also at a protein level. In adolescent VPA-exposed rats,
we observed a statistically significant increase of Olig2
protein expression in the PfC, a significant decrease in
the Cb, and a trend toward a decrease in the HPC (−
27.24%) (Fig. 6b). A more detailed analysis of the brain
areas revealed subtler modifications in Olig2-positive
cells distribution. In particular, in VPA-exposed rats we
observed a significant increase in the number of
Olig2-positive cells in the GL of the Cb and in the DG
of the HPC, and a statistically significant reduction of
Olig2-positive cells in the CA1 and CA2 of the same an-
imals (Fig. 6c, d). In adult (PND 90) rats prenatally ex-
posed to VPA, a significant decrease of Olig2 mRNA
was observed solely in the HPC (Fig. 7a). On the con-
trary, the Olig2 protein was increased in the HPC of
these animals (Fig. 7b). The VPA-exposed rats also
showed more Olig2-positive cells in the ML of the Cb
and in the CA1 (Fig. 7c, d).
Collectively, these results demonstrate that the pre-
natal exposure to VPA modifies oligodendrocytes at both
the transcriptional and translational levels, and that
these changes occur mainly in the PfC and in the HPC.
Of note, these alterations are particularly evident during
adolescence, but seem to be compensated in adulthood.
Microglia in ASD model rats
To characterize microglia in this rat model of ASD, we
analyzed transcription and expression of CD11b, a
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marker of microglia activation, and Iba1, a Ca2+-binding
protein constitutively expressed by both surveillant and
activated microglia. In VPA-exposed rats at PND 13, we
observed a significant increase of CD11b mRNA in PfC
and HPC, and no substantial change in the protein ex-
pression except for a trend toward an increase of this
marker in PfC (+ 54.36%) (Fig. 8a, b). At the same age,
we detected a significant increase of Iba1 mRNA in the
Cb of VPA-exposed rats (Fig. 8c). We also found a sig-
nificant increase in the number of Iba-positive cells in
the ML of the Cb of VPA-exposed rats with a significant
decrease in the CA3 of the same animals (Fig. 8e, f ).
Adolescent (PND 35) rats displayed more pronounced
modifications. A significant increase of both transcription
Fig. 2 Effect of prenatal VPA exposure on astrocytes in infancy. Analysis of the neurotrophin S100B and the GFAP in the PfC, Cb, and HPC of
healthy- (open bars, Veh) and autistic-like (black bars, VPA) infant rats (PND 13). Representation of the relative concentration of S100B (a) and
GFAP (c) in VPA animals compared to control (Veh), normalized to both TBP and HPRT (ΔΔCq; N = 3, in triplicate). Representative western blots
for S100B (b) and GFAP (d) proteins, and densitometric analyses are normalized to β-actin used as loading control. Results are expressed as
percentage of control (Veh) (N = 3, in triplicate). Representative fluorescence micrographs of GFAP (green) staining in the PfCGL and MLof Cb, and
CA1, CA2, CA3, and the hilus of the DG of the HPC. Nuclei were stained with Hoechst (blue) (e). The images have been analyzed by counting the
number of GFAP-positive cells in 2.4 × 105 μm3 (scale bar 50 μm; N = 3, 4 times) (f). All data are presented as means ± SEM. Statistical analysis was
performed by t test (*p < 0.05; ***p < 0.001 vs Veh group)
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and expression of CD11b in the PfC of VPA-exposed ani-
mals compared to control rats was detected (Fig. 9a, b).
Moreover, a significant increase of Iba1 mRNA was found
in the PfC of VPA-exposed rats, whereas, in the same ani-
mals, we observed reduced transcription in the HPC
(Fig. 9c). No changes of protein expression of Iba1 were
observed (Fig. 9d). The number of Iba1-positive cells
increased in the GL of the Cb and in the CA1 of adoles-
cent (PND 35) VPA-exposed rats (Fig. 9e, f ).
In adult rats (PND 90), no modifications of CD11b
and Iba1 protein transcription and expression was ob-
served, except for a trend toward an increase of CD11b
expression in PfC (+ 47.04%) and Cb (+ 41.26%), and a
significant decrease of Iba1 mRNA in the HPC of the
Fig. 3 Effect of the prenatal VPA exposure on astrocytes in adolescence. Evaluation of the neurotrophin S100B and the cytoskeletal GFAP in the
PfC, Cb, and HPC of healthy- (open bars, Veh) and autistic-like (black bars, VPA) adolescent rats (PND 35). Representation of the relative concentration
of S100B (a) and GFAP (c) in VPA animals compared to control (Veh), normalized to both TBP and HPRT (ΔΔCq; N = 3, in triplicate). Representative
western blots for S100B (b) and GFAP (d) proteins, and densitometric analyses normalized to β-actin used as loading control. Results are expressed as
percentage of control (Veh) (N = 3, in triplicate). Representative fluorescence micrographs of GFAP (green) staining in the PfC, GL and ML of Cb, and
stratum radiatum of CA1, CA2, CA3, and the hilus of the DG of the HPC. Nuclei were stained with Hoechst (blue) (e). The images have been analyzed
by counting the number of GFAP-positive cells in 2.4 × 105 μm3 (scale bar 50 μm; N = 3, 4 times) (f). All data are presented as means ± SEM. Statistical
analysis was performed by t test (*p < 0.05; **p < 0.01; ***p < 0.001 vs Veh group)
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same animals (Fig. 10a–d). At PND 90, the number of
Iba1-positive cells was significantly reduced in PfC, CA1,
and CA2 of rats prenatally exposed to VPA, while more
Iba1-positive cells were detected in the GL of the Cb of
the same animals (Fig. 10e, f ).
Taken together, these results indicate that the prenatal
VPA exposure modifies microglia and that these changes
occur mainly in the PfC and in the HPC. Moreover, we
observed that the prenatal VPA exposure switches
microglial phenotypes from resting to activated in infant
Fig. 4 Effect of the prenatal VPA exposure on astrocytes in adulthood. Evaluation of the neurotrophin S100B and the cytoskeletal GFAP in the
PfC, Cb, and HPC of healthy- (open bars, Veh) and autistic-like (black bars, VPA) adult rats (PND 90). Representation of the relative concentration of
S100B (a) and GFAP (c) in VPA animals compared to control (Veh), normalized to both TBP and HPRT (ΔΔCq; N = 3, in triplicate). Representative
western blots for S100B (b) and GFAP (d) proteins, and densitometric analyses normalized to β-actin used as loading control. Results are expressed as
percentage of control (Veh) (N = 3, in triplicate). Representative fluorescence micrographs of GFAP (green) staining in the PfC, GL and ML of Cb, and
stratum radiatum of CA1, CA2, CA3, and the hilus of the DG of the HPC. Nuclei were stained with Hoechst (blue) (e). The images have been analyzed
by counting the number of GFAP-positive cells in 2.4 × 105 μm3 (scale bar 50 μm; N = 3, 4 times) (f). All data are presented as means ± SEM. Statistical
analysis was performed by t test (*p < 0.05; ***p < 0.001 vs Veh group)
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and adolescent rats while this phenomenon is somewhat
mitigated in adulthood.
Discussion
All three types of neuroglia are critically important for
normal development of the CNS and for formation of
neuronal ensembles. Astrocytes assist synaptogenesis [17,
18], while astrocytes together with microglia shape neur-
onal networks through synaptic pruning and removal of
redundant synaptic contacts [45–47]. Functional insuffi-
ciency of neuroglia leads to neurodevelopmental patholo-
gies [48, 49]. The role of neuroglial components in ASD
has received much attention recently, when several lines
of evidence have demonstrated glia-specific alterations in
animal models of ASD as well as in patients suffering from
this disorder (for recent reviews see [48, 49]). The tran-
scriptome analysis of the brains of ASD patients identified
significant association of the pathology with genes linked
to reactive gliosis and neuroinflammation [50]. Increased
expression of astroglia-specific proteins aquaporin-4 and
connexin43 has been found in the autistic human tissue
[51]; increase in GFAP expression and astroglial hyper-
trophy was also observed with cerebellum demonstrating
most prominent changes [52]. Microglial activation and
increase in pro-inflammatory factors were other character-
istic features of ASD brain tissue [52–54].
These findings support the notion of glia-related
pathological developments that may exacerbate or even
Fig. 5 Effect of the prenatal VPA exposure on oligodendrocytes in infancy. Evaluation of the transcription factor Olig2 in the PfC, Cb, and HPC of
healthy- (open bars, Veh) and autistic-like (black bars, VPA) infant rats (PND 13). Representation of the relative concentration of Olig2 (a) in VPA
animals compared to control (Veh), normalized to both TBP and HPRT (ΔΔCq; N = 3, in triplicate). Representative western blots for Olig2 protein
and densitometric analyses normalized to β-actin used as loading control (b). Results are expressed as percentage of control (Veh) (N = 3, in
triplicate). Representative fluorescence micrographs of Olig2 (green) staining in the PfC, GL and ML of Cb, and stratum radiatum of CA1, CA2,
CA3, and the hilus of the DG of the HPC. Nuclei were stained with Hoechst (blue) (c). The images have been analyzed by counting the number
of Olig2-positive cells in 2.4 × 105 μm3 (scale bar 50 μm; N = 3, 4 times) (d). All data are presented as means ± SEM. Statistical analysis was performed by
t test (*p < 0.05; ***p < 0.001 vs Veh group)
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drive ASD evolution. Indeed, the autistic brain is af-
fected already at the early developmental stages, when
loss of function of microglia and astrocytes can affect
formation of synaptically connected neuronal networks.
Equally important could be the contribution of oligoden-
drocytes, which shape the brain connectome. Expression
of specific markers associated with cells of oligodendro-
glial lineage (including for example oligodendrocyte
transcription factor 1/2 or myelin basic protein) is
increased in the cerebella of autistic patients [55]. The
single nucleotide polymorphisms of the central oligo-
dendroglial differentiation regulator gene DUSP15 were
identified in the brains of ASD patients [56], while many
components of a molecular network associated with
ASD are specifically enriched in oligodendroglia and
white matter [57]. Changes in oligodendroglia and hence
changes in white matter may be linked to a rather char-
acteristic ASD-associated increase in the brain size (see
for examples [58, 59]).
Astroglial as well as microglial abnormalities have
been detected in animal models of several types of ASD
associated with expression of pathologically modified
genes; these include the Rett syndrome, fragile X syn-
drome, and tuberous sclerosis. In the Rett syndrome that
arises from loss-of-function mutations in the X-linked
MeCP2 encoding methyl-CpG-binding protein 2, the
glial pathological phenotype has been clearly revealed.
Microglial cells lacking MeCP2 triggered excitotoxicity
Fig. 6 Effect of the prenatal VPA exposure on oligodendrocytes in adolescence. Evaluation of the transcription factor Olig2 in the PfC, Cb, and
HPC of healthy- (open bars, Veh) and autistic-like (black bars, VPA) adolescent rats (PND 35). Representation of the relative concentration of Olig2
(a) in VPA animals compared to control (Veh), normalized to both TBP and HPRT (ΔΔCq; N = 3, in triplicate). Representative western blots for
Olig2 protein and densitometric analyses normalized to β-actin used as loading control (b). Results are expressed as percentage of control (Veh)
(N = 3, in triplicate). Representative fluorescence micrographs of Olig2 (green) staining in the PfC, GL and ML of Cb, and stratum radiatum of CA1,
CA2, CA3, and the hilus of the DG of the HPC. Nuclei were stained with Hoechst (blue) (c). The images have been analyzed by counting the
number of Olig2-positive cells in 2.4 × 105 μm3 (scale bar 50 μm; N = 3, 4 times) (d). All data are presented as means ± SEM. Statistical analysis was
performed by t test (*p < 0.05; **p < 0.01; ***p < 0.001 vs Veh group)
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through excessive release of glutamate [60]; whereas
MeCP2-deficient astrocytes lost their ability to support
neuronal growth and dendritic ramifications in vitro
[61]. In the fragile X syndrome (which results from the
loss of Fmr1 gene function), increased astroglial reactiv-
ity has been observed (in mice with genetic deletion of
Fmr1 gene) [62].
To summarize, the gliopathology in the ASD context
is mainly represented by glial reactivity, which further
highlights the contribution of neuroinflammation with
both processes apparently having pathological signifi-
cance. In this context, we asked ourselves whether the
same reactive changes are pronounced in a rodent
model of ASD resulting from in utero exposure to VPA,
a widely used antiepileptic drug. The use of VPA has
clinical significance as indeed VPA treatment during
pregnancy has been related with a higher risk of ASD in
the exposed children [7, 8]. Despite this evidence, recent
epidemiological studies show that the public awareness
of such an association is still limited [63].
Rodents prenatally exposed to VPA are widely used as a
preclinical model of ASD [9, 11, 64]. The VPA-treated ani-
mals display several ASD-like symptoms in the course of
development. These animals show impairment of the
communicative capabilities, alteration of the social reper-
toire, stereotypical behavior, and anxiety [40, 65]. In par-
ticular, in line with previous studies [66, 67], we found
that the infant male offspring born from VPA-treated rats
exhibit reduced ability to interact with their mothers,
since they emit less ultrasonic vocalizations when isolated
Fig. 7 Effect of the prenatal VPA exposure on oligodendrocytes in adulthood. Evaluation of the transcription factor Olig2 in the PfC, Cb, and HPC
of healthy- (open bars, Veh) and autistic-like (black bars, VPA) adult rats (PND 90). Representation of the relative concentration of Olig2 (a) in VPA
animals compared to control (Veh), normalized to both TBP and HPRT (ΔΔCq; N = 3, in triplicate). Representative western blots for Olig2 protein
and densitometric analyses normalized to β-actin used as loading control (b). Results are expressed as percentage of control (Veh) (N = 3, in triplicate).
Representative fluorescence micrographs of Olig2 (green) staining in the PfC, GL and ML of Cb, and stratum radiatum of CA1, CA2, CA3, and the hilus
of the DG of the HPC. Nuclei were stained with Hoechst (blue) (c). The images have been analyzed by counting the number of Olig2-positive cells in
2.4 × 105 μm3(scale bar 50 μm; N = 3, 4 times) (d). All data are presented as means ± SEM. Statistical analysis was performed by t test (*p < 0.05;
**p < 0.01; ***p < 0.001 vs Veh group)
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from their mothers and siblings. This feature is accom-
panied by the inability of VPA-exposed pups to recognize
familiar from unfamiliar odors, this being an early sign of
the impairment in social recognition [66, 68, 69]. All these
aspects negatively affect the social postnatal development
of the VPA-exposed offspring and persist through adoles-
cence and adulthood [40]. Indeed, VPA-exposed rats
showed altered sociability in the three chamber test and
increased stereotypic behavior in the hole board test. Our
results are in agreement with those obtained by other re-
searchers showing that a single injection of VPA to preg-
nant rats [65, 68, 70, 71] or mice [66, 72] on gestational
day 12.5 yielded offspring with a behavioral pattern strik-
ingly similar to that observed in autism. Beside behavioral
Fig. 8 Effect of the prenatal VPA exposure on microglia in infancy. Evaluation of the cluster of differentiation 11b (CD11b) and Iba1 in the PfC, Cb,
and HPC of healthy- (open bars, Veh) and autistic-like (black bars, VPA) infant rats (PND 13). Representation of the relative concentration of CD11b
(a) and Iba1 (c) in VPA animals compared to control (Veh), normalized to both TBP and HPRT (ΔΔCq; N = 3, in triplicate). Representative western
blots for CD11b (b) and Iba1 (d) proteins, and densitometric analyses normalized to β-actin used as loading control. Results are expressed as
percentage of control (Veh) (N = 3, in triplicate). Representative fluorescence micrographs of Iba1 (green) staining in the PfC, GL and ML of Cb,
and stratum radiatum of CA1, CA2, CA3, and the hilus of the DG of the HPC. Nuclei were stained with Hoechst (blue) (e). The images have been
analyzed by counting the number of Iba1-positive cells in 2.4 × 105 μm3 (scale bar 50 μm; N = 3, 4 times) (f). All data are presented as means ±
SEM. Statistical analysis was performed by t test (*p < 0.05; **p < 0.01; ***p < 0.001 vs Veh group)
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alterations, rats exposed to VPA in utero demonstrate mo-
lecular and metabolic abnormalities. Very recent experi-
ments demonstrated that VPA exposure impairs repair of
DNA damage [41], modifies cholesterol/isoprenoid me-
tabolism, and reduces the number of oligodendrocytes
leading to lower myelin and cholesterol levels in the HPC
of adolescent VPA-exposed rats [44].
Conclusions
Here, we extend this scenario by showing that prenatal
VPA exposure induces autistic-like behaviors and does
affect neuroglia. Modifications identified are brain re-
gion- and age-dependent. The changes in glia which we
observed in VPA-exposed rats have been rather modest
and occurred mostly at young ages; moreover, the
Fig. 9 Effect of the prenatal VPA exposure on microglia in adolescence. Evaluation of the cluster of differentiation 11b (CD11b) and Iba1 in the
PfC, Cb, and HPC of healthy- (open bars, Veh) and autistic-like (black bars, VPA) adolescent rats (PND 35). Representation of the relative concentration
of CD11b (a) and Iba1 (c) in VPA animals compared to control (Veh), normalized to both TBP and HPRT (ΔΔCq; N = 3, in triplicate). Representative
western blots for CD11b (b) and Iba1 (d) proteins, and densitometric analyses normalized to β-actin used as loading control. Results are expressed as
percentage of control (Veh) (N = 3, in triplicate). Representative fluorescence micrographs of Iba1 (green) staining in the PfC, GL and ML of Cb, and
stratum radiatum of CA1, CA2, CA3, and the hilus of the DG of the HPC. Nuclei were stained with Hoechst (blue) (e). The images have been analyzed
by counting the number of Iba1-positive cells in 2.4 × 105 μm3 (scale bar 50 μm; N = 3, 4 times) (f). All data are presented as means ± SEM. Statistical
analysis was performed by t test (*p < 0.05; **p < 0.01; ***p < 0.001 vs Veh group)
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changes were quite heterogeneous as they differ between
brain regions, and often we have not seen obvious cor-
relation between expression of mRNA and respective
protein. In line with previous findings [24, 71], some
hints for astrogliotic response were found in young ani-
mals, in which the density of GFAP-positive astrocytes
has increased in the cortical regions. This increase went
in parallel with elevated GFAP mRNA, without however
changes in protein content. In adult rats, the number of
GFAP-positive astrocytes was increased in CA3 but de-
creased in CA1 region and in cerebellum. Finally, in the
mature rats, numbers of GFAP-positive cells were in-
creased in Cb and CA2 hippocampal area, with no
changes in expression of GFAP and S100B at a protein
Fig. 10 Effect of the prenatal exposure to VPA on microglia in adulthood. Evaluation of the cluster of differentiation 11b (CD11b) and Iba1 in the
PfC, Cb, and HPC of healthy- (open bars, Veh) and autistic-like (black bars, VPA) adult rats (PND 90). Representation of the relative concentration of
CD11b (a) and Iba1 (c) in VPA animals compared to control (Veh), normalized to both TBP and HPRT (ΔΔCq; N = 3, in triplicate). Representative
western blots for CD11b (b) and Iba1 (d) proteins, and densitometric analyses normalized to β-actin used as loading control. Results are expressed as
percentage of control (Veh) (N = 3, in triplicate). Representative fluorescence micrographs of Iba1 (green) staining in the PfC, GL and ML of Cb, and
stratum radiatum of CA1, CA2, CA3, and the hilus of the DG of the HPC. Nuclei were stained with Hoechst (blue) (e). The images have been analyzed
by counting the number of Iba1-positive cells in 2.4 × 105 μm3 (scale bar 50 μm; N = 3, 4 times) (f). All data are presented as means ± SEM. Statistical
analysis was performed by t test (*p < 0.05; **p < 0.01; ***p < 0.001 vs Veh group)
Bronzuoli et al. Molecular Autism            (2018) 9:66 Page 15 of 17
level. At the same time, the changes in expression of
neuroglial markers seem to be rather mild, with neuroin-
flammatory phenotype being present mainly in young
ages and being ameliorated in adulthood.
All in all, the results we obtained in VPA-exposed rats
are heterogeneous and intricate and reflect the complex-
ity of the molecular and cellular mechanisms underlying
ASD. Indeed, autism is a complex disease, whose clinic
features are multifaceted and intricate like equally com-
plex and subtle should be the molecular changes causing
these phenotypes.
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